Migraine - Drug Pipeline Landscape, 2023

Migraine - Drug Pipeline Landscape, 2023

Migraine is a neurological disorder that is associated with recurrent headaches. The headache is characterized by affecting one side of the head, pulsating, moderate to severe in intensity which last for few hours to three days.

The underlying cause of migraine is unknown. It is believed that, migraine may be due to a mixture of environmental triggers and genetical factors. Change in hormonal levels during puberty may also affect the cause of migraine. Triggering factors include fatigue, certain foods, alcohol, and whether. Psychological stress quoted to be a risk factor.

The symptoms of migraine is presented one or two days before the attack, which is presented as constipation, mood changes, fatigue, fluid retention, frequent yawning, and increased urination. Few people experience migraine aura, including visual phenomena, vision loss, pins and needles sensation in arm and legs, weakness or numbness in the face and difficulty speaking. Symptoms during migraine attack includes pain on one of the head, pain throbbing or pulsing, sensitivity to light, sound, smell and touch, and also experience nausea and vomiting.

The migraine diagnosis is based on medical history, symptoms, physical and neurological examination, Neuroimaging tests are used to find other causes of headaches which includes MRI and CT scans.

The treatment plan of migraines includes the combination of lifestyle adjustments, OTC pain or migraine medications like NSAIDs, triptans, dihydroergotamine, CGRP antagonists, opioid medications, anti-nausea drugs, alternative care includes meditation, acupressure or acupuncture.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Migraine treatment such as Zavegepant, AXS-07, STS101, and others. Key players involved in the development of therapies to treat Migraine are Eli Lilly and Co, AbbVie, Biohaven Pharmaceuticals and others. Four drugs are under late-stage Pre-Registration Stage, 7 drugs are in Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. Biohaven Ltd is expecting zavegepant nasal spray with a Prescription Drug Fee Act (PDUFA) goal date set for the Q1 2023. In Nov 2022, Satsuma Pharmaceuticals announced top-line results of SUMMIT Phase III trial of STS101.

Report Highlights

Global Insight Service's, Migraine - Drug Pipeline Landscape, 2023 report provides an overview of the Migraine pipeline drugs. This report covers detailed insights on Migraine drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Migraine pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Migraine - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Migraine
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Migraine - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Late-Stage Drugs - Pre-Registration
5.1.1 Atogepant
5.1.2 Cannabis
5.1.3 Dihydroergotamine
5.1.4 Zavegepant
5.2 Late-Stage Drugs - Filing Rejected
5.2.1 M207
5.3 Clinical Stage Drugs - Phase III
5.3.1 AXS-07
5.3.2 Eptinezumab
5.3.3 Erenumab
5.3.4 Galcanezumab
5.3.5 Lasmiditan
5.3.6 Rimegepant
5.3.7 STS-101
5.4 Clinical Stage Drugs - Phase II
5.4.1 ABP-450
5.4.2 AGX-201
5.4.3 ALLOD 2
5.4.4 B244
5.4.5 C-AM-01
5.4.6 CL-H1T
5.4.8 LAT8881
5.4.9 Lu AG09222
5.4.10 LY-3451838
5.4.11 Sepranolone
5.4.12 Topofen
5.4.13 Tricaprilin
5.4.14 TRM-201
5.5 Clinical Stage Drugs - Phase I
5.5.1 AST-004
5.5.2 EP102
5.5.3 NYPRG-101
5.5.4 PN-6047
5.5.5 PUR3100
5.5.6 SAN711
5.5.7 Sumatriptan Succinate
5.5.8 TRV250
5.5.9 UB 313
5.5.10 XC101
5.6 Early-Stage Drugs - Preclinical
5.6.1 BETR-001
5.6.2 C5
5.6.3 Drug for Migraine
5.6.4 IGF-1
5.6.5 JS010
5.6.6 kappa-opioid receptor agonists
5.6.7 KCZ-1279
5.6.8 MTR-106
5.6.9 Pear-014
5.6.10 PH80-M
5.6.11 PL37
5.6.12 ReViVox
5.6.13 Sumatriptan
5.6.14 TNX1900
5.6.15 URB937
5.7 Early-Stage Drugs - Discovery
5.7.1 CR601
5.7.2 CYM51317
5.7.3 Drug for Migraine
5.7.4 Drug for Migraine
5.8 Unknown Stage Drugs
5.8.1 DaxibotulinumtoxinA
5.8.2 NAL1606
5.8.3 Sumatriptan
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 AbbVie Inc
9.2 Achelios Therapeutics Inc
9.3 AEON Biopharma Inc
9.4 AgoneX Biopharmaceuticals Inc
9.5 Allodynic Therapeutics LLC
9.6 Amgen Inc
9.7 Amneal Pharmaceuticals Inc
9.8 AOBiome LLC
9.9 Arovella Therapeutics Ltd
9.10 Asarina Pharma AB
9.11 Astrocyte Pharmaceuticals Inc
9.12 Axsome Therapeutics Inc
9.13 Better Life Pharmaceuticals Inc
9.14 Biohaven Pharmaceutical Holding Company Ltd
9.15 Blackthorn Therapeutics Inc
9.16 Cerecin Pte Ltd
9.17 Ceruvia Lifesciences LLC
9.18 Charleston Laboratories Inc
9.19 Crossject SA
9.20 Crystec Ltd
9.21 Curatis AG
9.22 DelNova Inc
9.23 Eli Lilly and Co
9.24 Epalex Corp
9.25 Exxel Pharma Inc
9.26 Gubra ApS
9.27 H. Lundbeck AS
9.28 HEC Pharma Co Ltd
9.29 IACTA Pharmaceuticals Inc
9.30 Ionis Pharmaceuticals Inc
9.31 Kallyope Inc
9.32 Kissei Pharmaceutical Co Ltd
9.33 Lateral Pharma Pty Ltd
9.34 NAL Pharmaceuticals Ltd
9.35 Panaxia Pharmaceutical Industries Ltd
9.36 PassPort Technologies Inc
9.37 Pear Therapeutics
9.38 Peptide Logic LLC
9.39 Pharmnovo AB
9.40 Pherin Pharmaceuticals Inc
9.41 Pulmatrix Inc
9.42 Revance Therapeutics Inc
9.43 Saniona AB
9.44 Satsuma Pharmaceuticals Inc
9.45 Seurat Therapeutics Inc
9.46 Shanghai Junshi Bioscience Co Ltd
9.47 Sorrento Therapeutics Inc
9.48 Tonix Pharmaceuticals
9.49 Tremeau Pharmaceuticals Inc
9.50 Trevena Inc
9.51 TrioxBio Inc
9.52 Vaxxinity Inc
9.53 Xoc Pharmaceuticals Inc
9.54 Zosano Pharma Corp
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details - AXS-07/Axsome Therapeutics Inc
Table 2.2 Clinical Trial Details - Eptinezumab/H. Lundbeck AS
Table 2.3 Clinical Trial Details - Erenumab/Amgen Inc
Table 2.4 Clinical Trial Details - Galcanezumab/Eli Lilly and Co
Table 2.5 Clinical Trial Details - Lasmiditan/Eli Lilly and Co
Table 2.6 Clinical Trial Details - Rimegepant/Biohaven Pharmaceutical Holding Company Ltd
Table 2.7 Clinical Trial Details - STS-101/Satsuma Pharmaceuticals Inc
Table 2.8 Clinical Trial Details - ABP-450/AEON Biopharma Inc
Table 2.9 Clinical Trial Details - AGX-201/AgoneX Biopharmaceuticals Inc
Table 2.10 Clinical Trial Details - B244/AOBiome LLC
Table 2.11 Clinical Trial Details - CL-H1T/Charleston Laboratories Inc
Table 2.12 Clinical Trial Details - IONIS-PKKRx/Ionis Pharmaceuticals Inc
Table 2.13 Clinical Trial Details - LAT8881 /Lateral Pharma Pty Ltd
Table 2.14 Clinical Trial Details - Lu AG09222/H. Lundbeck AS
Table 2.15 Clinical Trial Details - LY-3451838/Eli Lilly and Co
Table 2.16 Clinical Trial Details - Sepranolone/Asarina Pharma AB
Table 2.17 Clinical Trial Details - Topofen/Achelios Therapeutics Inc
Table 2.18 Clinical Trial Details - Tricaprilin/Cerecin Pte Ltd
Table 2.19 Clinical Trial Details - PUR3100/Pulmatrix Inc
Table 2.20 Clinical Trial Details - SAN711/Saniona AB
Table 2.21 Clinical Trial Details - Sumatriptan Succinate/Sorrento Therapeutics Inc
Table 2.22 Clinical Trial Details - UB 313/Vaxxinity Inc
Table 2.23 Clinical Trial Details - XC101/Xoc Pharmaceuticals Inc
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Migraine, 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Migraine, 2023
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Migraine, 2023
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Migraine, 2023
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Migraine, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings